Cancer Diagnostics Lab Offers Two Week Turnaround Time
By LabMedica International staff writers Posted on 02 Sep 2015 |
An advanced cancer molecular testing laboratory can provide complete information on some 562 cancer-related genes with a turn-around time of less than two weeks.
Ashion Analytics (Phoenix, AZ, USA) a [US] Food and Drug Administration CLIA (Clinical Laboratory Improvement Amendments) certified and CAP (College of American Pathologists)-accredited molecular cancer testing laboratory is now offering its Genomic Enabled Medicine (GEM) Cancer Panel to assist doctors in treating cancer patients.
The 562 gene panel includes coding regions for 540 genes, and non-coding regions for an additional 22 genes that are known to be structurally rearranged or altered in cancer. Additional regions for the identification of specific structural variants are also included. Samples are tested at the company's Phoenix (AZ, USA) laboratory utilizing the targeted enrichment method followed by sequencing on an Illumina, Inc. (San Diego, CA, USA) HiSeq 2500 analytical instrument. The HiSeq 2500 System is a powerful and efficient ultra-high-throughput sequencing system that supports the broadest range of applications and study sizes. Results are evaluated using methods that include analysis of single nucleotide variants, insertions/deletions, structural variants, focal and whole genome copy number.
Ashion Analytics also supports research studies and clinical trials for investigators in university, hospital, and pharmaceutical industry settings with expanded whole exome sequencing with its GEM-GWTM test, which also includes analysis of copy number events and structural variation, as well as RNA sequencing.
"Our understanding of genomics today is fundamentally changing the way we view and treat cancer, and we believe the future holds even greater promise," said Dr. Michael Demeure, executive vice-president and general manager of Ashion Analytics. "As a physician who continues to treat cancer patients, I see every day the critical need to develop better diagnostics as well as new, more effective and less toxic treatment options. This unmet need drives all our efforts at Ashion Analytics."
Related Links:
Ashion Analytics
Illumina, Inc.
Ashion Analytics (Phoenix, AZ, USA) a [US] Food and Drug Administration CLIA (Clinical Laboratory Improvement Amendments) certified and CAP (College of American Pathologists)-accredited molecular cancer testing laboratory is now offering its Genomic Enabled Medicine (GEM) Cancer Panel to assist doctors in treating cancer patients.
The 562 gene panel includes coding regions for 540 genes, and non-coding regions for an additional 22 genes that are known to be structurally rearranged or altered in cancer. Additional regions for the identification of specific structural variants are also included. Samples are tested at the company's Phoenix (AZ, USA) laboratory utilizing the targeted enrichment method followed by sequencing on an Illumina, Inc. (San Diego, CA, USA) HiSeq 2500 analytical instrument. The HiSeq 2500 System is a powerful and efficient ultra-high-throughput sequencing system that supports the broadest range of applications and study sizes. Results are evaluated using methods that include analysis of single nucleotide variants, insertions/deletions, structural variants, focal and whole genome copy number.
Ashion Analytics also supports research studies and clinical trials for investigators in university, hospital, and pharmaceutical industry settings with expanded whole exome sequencing with its GEM-GWTM test, which also includes analysis of copy number events and structural variation, as well as RNA sequencing.
"Our understanding of genomics today is fundamentally changing the way we view and treat cancer, and we believe the future holds even greater promise," said Dr. Michael Demeure, executive vice-president and general manager of Ashion Analytics. "As a physician who continues to treat cancer patients, I see every day the critical need to develop better diagnostics as well as new, more effective and less toxic treatment options. This unmet need drives all our efforts at Ashion Analytics."
Related Links:
Ashion Analytics
Illumina, Inc.
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Pathology News
- New WHO Reporting System for Lung Cytopathology to Enhance Diagnostic Accuracy
- Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer
- Novel AI-Powered Method for Tissue Analysis Improves Understanding of Disease Pathology
- Noninvasive Technology Detects Rare Cancer Cells in Blood
- AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time
- New Tool Enables Better Classification of Inherited Disease-Causing Variants
- Groundbreaking CRISPR Screen Technology Rapidly Determines Disease Mechanism from Tissues
- New AI Tool Classifies Brain Tumors More Quickly and Accurately
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests